GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Novartis Ag (NVS) [hlAlert]

Rating:
Buy NVS
up 57.67 %

Barrons 10 Favorite Stocks for 2013 - NOVARTIS

Posted on: Thursday,  Jan 3, 2013  1:40 AM ET by Barron's favorite stocks for 2013

Barron's favorite stocks for 2013 rated Buy Novartis Ag (NYSE: NVS) on 12/10/2012, when the stock price was $62.56.
Since then, Novartis Ag has gained 57.67% as of 01/14/2016's recent price of $98.64.
If you would have followed this Barron's favorite stocks for 2013's recommendation on NVS, you would have gained 57.67% of your investment in 1130 days.

Novartis AG, incorporated on February 29, 1996, is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare products. The Company?s healthcare solutions portfolio includes medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products. Its businesses are divided on a worldwide basis into the four operating divisions: Pharmaceuticals, which comprises brand-name patented pharmaceuticals; Vaccines and Diagnostics, which focuses on human vaccines and blood-testing diagnostics; Sandoz, which consists generic pharmaceuticals, and Consumer Health, which includes over-the-counter medicines, animal health medicines, and contact lenses and lens-care products. It operates in approximately 140 countries. In September 2009, Novartis AG announced that its Sandoz division has completed the acquisition of EBEWE Pharma's specialty generic injectables business.

With uncertainty roiling the market, the big question is not, will the market go up next year, but what stocks will go up. Think Apple, Royal Dutch Shell, JPMorgan Chase, and more.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/10/2012 4:00 PM Buy
1 year
62.56
as of 8/27/2015
1 Week down  -1.99 %
1 Month down  -4.02 %
3 Months down  -5.06 %
1 YTD up  22.71 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy